Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients
- PMID: 6409773
- DOI: 10.1055/s-2007-1018694
Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients
Abstract
Clinical factors which might influence the absorption of subcutaneously injected 125I-NPH insulin were studied in 101 diabetics. The disappearance curve was monoexponential after a delay period of 1.5 +/- 0.8 h (mean +/- SD). Lipohypertrophy significantly prolonged insulin absorption (half life (T1/2) = 11.2 +/- 3.1 h, p = 0.0001). Low bicarbonate levels increased the absorption (T1/2 3.9 +/- 2.3 h, p less than 0.05). Lean diabetics had a faster absorption (6.2 +/- 1.9 h) than normal weight diabetics (7.5 +/- 2.0 h, p less than 0.02). Sex, age, diabetes duration and injection depth did not influence T1/2. The half life was significantly inversely correlated to the resting subcutaneous blood flow (r = 0.882, p less than 0.01). The overall interindividual coefficient of variation for insulin absorption in nonketotic diabetics was 27.4%. Also considerable intra-patient day-to-day variation was found (24.5%), and between different injection sites (30.2%). These variations emphasize the drawbacks of conventional insulin therapy in the management of insulin-requiring diabetics.
Similar articles
-
Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.Horm Metab Res. 2003 Jul;35(7):434-8. doi: 10.1055/s-2003-41625. Horm Metab Res. 2003. PMID: 12931275 Clinical Trial.
-
Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.Dan Med Bull. 1991 Aug;38(4):337-46. Dan Med Bull. 1991. PMID: 1914533 Review.
-
Effects of leg exercise on insulin absorption in diabetic patients.N Engl J Med. 1978 Jan 12;298(2):79-83. doi: 10.1056/NEJM197801122980205. N Engl J Med. 1978. PMID: 619237 Clinical Trial.
-
Absorption and miscibility of regular porcine insulin after subcutaneous injection of insulin-treated diabetic patients.Diabetes Care. 1983 Jan-Feb;6(1):6-9. doi: 10.2337/diacare.6.1.6. Diabetes Care. 1983. PMID: 6341016
-
[From the concept of fast acting analogs to the properties of the insulin Lispro].Diabetes Metab. 1997 Sep;23 Suppl 3:45-9. Diabetes Metab. 1997. PMID: 9410552 Review. French.
Cited by
-
Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.Diabetologia. 2004 Apr;47(4):622-9. doi: 10.1007/s00125-004-1365-z. Diabetologia. 2004. PMID: 15298338 Clinical Trial.
-
Can technological solutions for diabetes replace islet cell function?Organogenesis. 2011 Jan-Mar;7(1):32-41. doi: 10.4161/org.7.1.14028. Epub 2011 Jan 1. Organogenesis. 2011. PMID: 21289480 Free PMC article. Review.
-
Role of Structured Education in Reducing Lypodistrophy and its Metabolic Complications in Insulin-Treated People with Type 2 Diabetes: A Randomized Multicenter Case-Control Study.Diabetes Ther. 2021 May;12(5):1379-1398. doi: 10.1007/s13300-021-01006-0. Epub 2021 Mar 18. Diabetes Ther. 2021. PMID: 33738775 Free PMC article.
-
The pharmacokinetics of two different concentrations of short-acting insulin, intermediate-acting insulin, and an insulin mixture following subcutaneous injection.Clin Investig. 1992 Jul;70(7):621-6. doi: 10.1007/BF00184810. Clin Investig. 1992. PMID: 1392436 Clinical Trial.
-
Clinical pharmacokinetics and pharmacodynamics of insulin aspart.Clin Pharmacokinet. 2001;40(9):641-59. doi: 10.2165/00003088-200140090-00002. Clin Pharmacokinet. 2001. PMID: 11605714 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical